Linked Life Data

9990473

Source:http://linkedlifedata.com/resource/pubmed/id/9990473

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-5-28
pubmed:abstractText
A total of 4241 consecutive clinical bacterial isolates from 10 North American medical centers were tested for susceptibility to trovafloxacin. Trovafloxacin was significantly more active than ciprofloxacin against Gram-positive bacteria, Acinetobacter spp., and Stenotrophomonas maltophilia, and resistance to trovafloxacin occurred in these groups only among isolates with high-level resistance (MIC > or = 16 micrograms/mL) to ciprofloxacin. With other species, the two drugs had comparable activity. Concerns about staphylococci and Pseudomonas aeruginosa with trovafloxacin MICs of 2.0 micrograms/mL (the upper end of the susceptible category) are discussed. Results of trovafloxacin disk diffusion test on more than 3200 nonfastidious isolates supported the FDA-approved zone size interpretive criteria when the MIC breakpoint of < or = 2.0 micrograms/mL is used to define the trovafloxacin-susceptible category.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0732-8893
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
33-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
pubmed:affiliation
Clinical Microbiology Institute, Wilsonville, OR 97070, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't